Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer

Fig. 4

Evaluation of clinical outcomes of patients who received matched targeted therapies. A Evaluation of the clinical outcomes of patients with exonic-breakpoint fusions detected by DNA NGS but not by RNA NGS and IHC. B Survival curves for exonic-breakpoint and intronic-breakpoint ALK fusions among patients with RNA NGS/IHC-validated ALK fusions

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us